US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

 
• By Cathy Kelly
Lilly is Seeking Biologics Status for its investigational obesity agent. • Source: Shutterstock

More from Pricing Debate

More from Market Access